U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561645) titled 'A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung' on April 15.
Brief Summary: This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Large Cell Neuroendocrine Carcinoma of the Lung
Intervention:
DRUG: Obrixtamig
Obrixtamig (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Three cycles of combined immunochemotherapy 3qw will be followed by maintenance with obrixtamig monotherapy until progression.
Recruitme...